While growth momentum in the domestic formulation industry slowed down in 2012-13 owing to a confluence of reasons, including the announcement of ceiling prices as per the DPCO 2013, July witnessed growth of 9.4 per cent with even the month’s Indian Pharma Market (IPM) value at Rs 6453 crores, better than the previous month.
For July 2013, amongst the top 10 corporates, Alkem registered growth of 23.4 per cent, Sun Pharma 15.6 and Cipla 14.7 per cent. 31 of the top 50 corporates crossed IPM growth in this month. Amongst the top 50 corporates, Biocon has the highest growth of 48.7 per cent followed by AstraZeneca at 45.5 per cent and Franco Indian at 23.5 per cent. Amongst the 11-20 ranked companies Aristo has shown a high growth of 22.8 per cent followed by Glenmark at 18.9 per cent and Torrent at 15.5 per cent. Amongst upcoming corporates Corona Remedies has grown at 135.5 per cent, Eris at 23 per cent and Akumentis at 22.9 per cent. Alkem has crossed Rs 2500 crores and Wanbury Rs 200 crores in the IPM.
| With Bonus Units at Full Value | ||||||||
| Val in Crs | Rank | MAT July -13 | Jul-13 | |||||
| CORPORATE | MAT | MTH | Val (Cr) | MS% | GR% | Val (Cr) | MS% | GR% |
| IPM | 72444 | 100.00 | 9.3 | 6453 | 100.00 | 9.4 | ||
| Abbott + Abbott HC + Novo | 1 | 1 | 4928 | 6.80 | 6.6 | 420 | 6.51 | 6.4 |
| Sun Pharma | 2 | 2 | 3685 | 5.09 | 19.0 | 337 | 5.23 | 15.6 |
| Cipla | 3 | 3 | 3651 | 5.04 | 7.3 | 314 | 4.86 | 14.7 |
| Zydus + Biochem | 4 | 4 | 3246 | 4.48 | 19.1 | 285 | 4.42 | 12.0 |
| Glaxo | 5 | 5 | 3167 | 4.37 | 2.0 | 260 | 4.03 | -5.5 |
| Ranbaxy | 6 | 6 | 2991 | 4.13 | 6.6 | 255 | 3.95 | 4.0 |
| Mankind | 7 | 7 | 2647 | 3.65 | 18.3 | 249 | 3.86 | 13.5 |
| Alkem + Cachet + Indchemie | 8 | 8 | 2528 | 3.49 | 13.2 | 245 | 3.80 | 23.4 |
| Pfizer + Wyeth | 9 | 10 | 2200 | 3.04 | 4.2 | 186 | 2.89 | 2.9 |
| Lupin | 10 | 9 | 2183 | 3.01 | 9.8 | 196 | 3.03 | 7.6 |
| Macleods | 11 | 11 | 1875 | 2.59 | 14.8 | 174 | 2.69 | 11.2 |
| Intas | 12 | 13 | 1798 | 2.48 | 14.6 | 155 | 2.40 | 5.4 |
| Emcure + Zuventus | 13 | 14 | 1713 | 2.36 | 11.8 | 152 | 2.36 | 14.8 |
| Aristo | 14 | 12 | 1704 | 2.35 | 11.8 | 164 | 2.54 | 22.8 |
| Dr. Reddys | 15 | 15 | 1597 | 2.21 | 11.3 | 138 | 2.14 | 13.1 |
| Sanofi-Aventis + Universal | 16 | 17 | 1550 | 2.14 | 5.2 | 134 | 2.08 | -0.5 |
| Glenmark | 17 | 16 | 1457 | 2.01 | 14.9 | 136 | 2.10 | 18.9 |
| USV | 18 | 18 | 1309 | 1.81 | 17.7 | 117 | 1.82 | 10.7 |
| Micro + Bal | 19 | 20 | 1307 | 1.80 | 3.4 | 113 | 1.75 | 2.3 |
| Torrent | 20 | 19 | 1256 | 1.73 | 16.9 | 116 | 1.79 | 15.5 |
The overall bonus market grew by nine per cent. Certain molecules like Amoxy- Clavulanic grew by 16 per cent, Cefixime 19 per cent which are a part of DPCO 2013.
From the therapy perspective, six therapies outgrew the IPM. The anti-infective market saw a growth of 14.6 per cent, while the respiratory market grew 27.6 per cent. The anti-diabetic market has grown at 2.8 per cent and cardiac at 7.2 per cent in chronic business. The anti-diabetic market felt the heat of the pioglitazone issue with these formulations down 74 per cent over July 12.
| Val in Crs | ||||
| Super Group | MAT June13 | GR% | Mth June13 | GR% |
| IPM | 72069 | 9.8 | 5899 | 4.8 |
| ANTI-INFECTIVES | 12700 | 8.1 | 987 | 7.5 |
| CARDIAC | 8754 | 11.5 | 728 | 3.3 |
| GASTRO INTESTINAL | 8195 | 10.4 | 711 | 2.8 |
| VITAMINS / MINERALS / NUTRIENTS | 6341 | 9.3 | 545 | -0.4 |
| RESPIRATORY | 5495 | 8.2 | 379 | 17.8 |
| PAIN / ANALGESICS | 5318 | 7.3 | 440 | 5.6 |
| ANTI DIABETIC | 4877 | 14.4 | 410 | 4.3 |
| GYNAECOLOGICAL | 4643 | 6.6 | 390 | -0.1 |
| NEURO / CNS | 4403 | 11.0 | 363 | 5.7 |
| DERMA | 3774 | 9.8 | 313 | 1.5 |
| OPHTHAL / OTOLOGICALS | 1290 | 10.1 | 109 | 3.3 |
| HORMONES | 1247 | 14.9 | 101 | 6.6 |
| OTHERS | 984 | 14.8 | 82 | 4.1 |
| ANTI-NEOPLASTICS | 921 | 20.1 | 84 | 26.3 |
| VACCINES | 875 | 4.8 | 75 | 4.7 |
| BLOOD RELATED | 865 | 4.4 | 74 | -3.5 |
| ANTI MALARIALS | 657 | 12.1 | 46 | 5.9 |
| SEX STIMULANTS / REJUVENATORS | 413 | 15.5 | 34 | 15.5 |
| STOMATOLOGICALS | 318 | 10.1 | 29 | 6.4 |
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total, MTH – Month, Val(Cr) – Value in Crores, MS per cent – Market Share in Percentage, GR per cent – Growth in percentage
For more information, visit http://www.aiocd.net